Quarterly report pursuant to Section 13 or 15(d)

EQUTY INVESTMENT (Details Narrative)

v3.19.2
EQUTY INVESTMENT (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended
Dec. 18, 2018
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
May 06, 2019
SHARE OF NET LOSSES OF EQUITY METHOD INVESTEE   $ (53,000) $ (149,000)  
Goodwill   3,392,000   3,392,000    
ILiAD [Member]            
Advisory and legal expenses       41,000    
ILiAD [Member] | Maximum [Member]            
Investment $ 5,000,000          
ILiAD [Member] | Tranche One [Member]            
Initial investment $ 2,500,000          
Description for the terms of allowed-to-proceed notice under aggrement On May 2, 2019, ILiAD notified the Company that it had received an "allowed to proceed" notice from the FDA permitting ILiAD to advance to the Phase 2b clinical study of its BP2E1 vaccine. ILiAD elected to permit its Class C investors (including the Company) to bifurcate their tranche 2 commitments such that 40% would be currently due and 60% (additional $1,500,000 investment by the Company) would be due when ILiAD receives satisfactory safety data from the clinical study.          
ILiAD [Member] | Tranche Two [Member]            
Initial investment   $ 2,500,000   $ 2,500,000    
ILiAD [Member] | Class C units [Member]            
Investment           $ 1,000,000
Units purchase           377,358
Price per unit           $ 2.65
Warrants to purchase units           124,528
Exercise price           $ 3.50
Ownership percentage           8.40%
ILiAD [Member] | Class C units [Member] | Maximum [Member]            
Investment $ 16,200,000          
ILiAD [Member] | Class C units [Member] | Tranche One [Member]            
Units purchase   1,111,111   1,111,111    
Price per unit   $ 2.25   $ 2.25    
ILiAD [Member] | Class C units [Member] | Tranche Two [Member]            
Units purchase 943,396          
Price per unit $ 2.65          
Warrants to purchase units 311,320          
Exercise price $ 3.50